The signal-regulatory protein CD47 mediates a “don't eat me” signal when it binds its receptor SIRPa, and this is thought to contribute to the resistance of tumors to phagocyte-dependent clearance. In Nature Medicine, Xu and colleagues show that therapeutic blockade of CD47 also leads to the activation of potent anti-tumor cytotoxic T lymphocyte (CTL) responses. Using syngeneic mouse tumor models, the authors find that blocking CD47 allows the sensing of tumor DNA and then triggers type I interferons. Acting on tumor-infiltrating dendritic cells, the type I interferons then drive the cross-presentation of tumor antigens to CTLs. These CTLs are essential for the anti-tumor effects of CD47 blockade. Therefore, in addition to simply preventing the phagocytosis of tumor cells, the CD47-SIRPa axis also protects tumors from destructive CTL responses. These findings reveal a new perspective on the underlying mechanism of therapeutic CD47 blockade.
Rights and permissions
About this article
Cite this article
Fehervari, Z. Don't eat me, activate me. Nat Immunol 16, 1113 (2015). https://doi.org/10.1038/ni.3303
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.3303